| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bianca Cheaib, Aurélie Auguste, Alexandra Lear. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chinese journal of cancer. vol 34. issue 1. 2015-06-04. PMID:25556614. |
although it is likely that inhibition of the pi3k/akt/mtor pathway may have little effect in unselected oc patients, certain histological types, such as clear cell or endometrioid oc with frequent phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic subunit alpha (pik3ca) and/or phosphatase and tensin homolog (pten) alterations, may be particularly suited to this approach. |
2015-06-04 |
2023-08-13 |
Not clear |
| Cheng-Fang Li, Chun-Xia Liu, Bing-Cheng Li, Yao-Yuan Shen, Xiao-Bin Cui, Wei Liu, Hong-Chao Dong, Li-Juan Pang, Wei-Hua Liang, Feng L. Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations. International journal of clinical and experimental pathology. vol 7. issue 7. 2015-05-14. PMID:25120743. |
our results revealed 2 mutations in 2 recurrent lesion samples, including one in exon 11 of the kit gene, resulting in a t-c substitution at position 1727 (l576p), the recurrent sample underwent histologic progression with "pleomorphic undifferentiated sarcoma-like" transformation; the other mutation was in exon 19 of the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca) gene, resulting in a g-a substitution at position 1624 (e542k). |
2015-05-14 |
2023-08-13 |
Not clear |
| Yanan Li, Yunzhi Zhou, Hongwu Wan. [Research status on molecular targeted therapy for squamous-cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. vol 17. issue 8. 2015-04-02. PMID:25130969. |
sqclc molecular targeted therapy mainly epidermal growth factor receptor (egfr), phosphoin-3-kinase catalytic alpha polypeptide (pik3ca), fibroblast growth factor receptor 1 (fgfr1), discoidin domain receptor 2 (ddr2), phosphatase and tensin homolog deleted on chromosome ten (pten), braf, met, insulin-like growth factor 1 receptor (igf-1r) and other as the target of the drug, some targeted drugs are being developed, and some targeted drugs have entered clinical trials. |
2015-04-02 |
2023-08-13 |
Not clear |
| Carlotta Costa, Hiromichi Ebi, Miriam Martini, Sean A Beausoleil, Anthony C Faber, Charles T Jakubik, Alan Huang, Youzhen Wang, Madhuri Nishtala, Ben Hall, Klarisa Rikova, Jean Zhao, Emilio Hirsch, Cyril H Benes, Jeffrey A Engelma. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer cell. vol 27. issue 1. 2015-03-13. PMID:25544637. |
byl719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (pi3k) catalytic subunit (p110a), is currently in clinical trials for the treatment of solid tumors, especially luminal breast cancers with pik3ca mutations and/or her2 amplification. |
2015-03-13 |
2023-08-13 |
Not clear |
| Hsien-Neng Huang, Ming-Chieh Lin, Wen-Chih Huang, Ying-Cheng Chiang, Kuan-Ting Ku. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 27. issue 7. 2015-02-21. PMID:24336158. |
a total of 68 ovarian clear cell carcinoma cases were collected and subjected to immunohistochemistry testing for arid1a, smarca2, smarca4, smarcb1 and phosphatase and tensin homolog (pten), mutation analysis for phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca) gene and fluorescence in situ hybridization for znf217 amplification. |
2015-02-21 |
2023-08-12 |
Not clear |
| Rona Yaeger, Andrea Cercek, Joanne F Chou, Brooke E Sylvester, Nancy E Kemeny, Jaclyn F Hechtman, Marc Ladanyi, Neal Rosen, Martin R Weiser, Marinela Capanu, David B Solit, Michael I D'Angelica, Efsevia Vakiani, Leonard B Salt. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. vol 120. issue 15. 2014-12-09. PMID:24737664. |
the current study was undertaken to determine the clinicopathologic characteristics, pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutation frequency, and outcomes after metastasectomy in patients with braf-mutant mcrc. |
2014-12-09 |
2023-08-13 |
Not clear |
| Qian-Qian Yu, Hao Wu, Xiang Huang, Hua Shen, Yong-Qian Shu, Bin Zhang, Cheng-Cheng Xiang, Shao-Min Yu, Ren-Hua Guo, Liang Che. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 68. issue 2. 2014-11-17. PMID:24486107. |
we investigated whether phosphoinositide-3-kinase catalytic subunit alpha (pik3ca) was a novel target of mir-1 in the nsclc cell line a549, and the mechanism of mir-1 inhibition of the tumorigenic properties of a549 cells is discussed. |
2014-11-17 |
2023-08-12 |
human |
| Xian-Fu Ke, Jie Fang, Xiao-Ning Wu, Chen-Huan Y. MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA. Biochemical and biophysical research communications. vol 450. issue 4. 2014-11-04. PMID:24996183. |
mir-203 overexpression also inhibited the protein expression of phosphoinositide 3-kinase catalytic subunit alpha (pik3ca), a direct target of mir-203 identified by bioinformatics, thereby suppressing the pi3k/akt pathway. |
2014-11-04 |
2023-08-13 |
mouse |
| Dong Choon Kim, Woo Jin Chung, Jae-Ho Lee, Byung Kuk Jang, Jae Seok Hwang, Koo Jeong Kang, Sun Young Kwo. Clinicopathological characteristics of PIK3CA and HBx mutations in Korean patients with hepatocellular carcinomas. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. vol 122. issue 10. 2014-11-03. PMID:24673525. |
progression of this disease is frequently associated with mutations in either phosphoinositide-3-kinase, catalytic, alpha (pik3ca) or hepatitis b virus x (hbx) gene. |
2014-11-03 |
2023-08-12 |
Not clear |
| Thanyanan Reungwetwattana, Grace Kho D. Targeted therapies in development for non-small cell lung cancer. Journal of carcinogenesis. vol 12. 2014-06-24. PMID:24574860. |
in non-small cell lung cancer (nsclc), the erbb family of receptors (e.g., egfr [epidermal growth factor receptor], her2 [human epidermal growth factor receptor 2]), ras (rat sarcoma gene), braf (v-raf murine sarcoma viral oncogene homolog b1), mapk (mitogen-activated protein kinase) c-met (c-mesenchymal-epithelial transition), fgfr (fibroblast growth factor receptor), ddr2 (discoidin domain receptor 2), pik3ca (phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit alpha)), pten (phosphatase and tensin homolog), akt (protein kinase b), alk (anaplastic lym phoma kinase), ret (rearranged during transfection), ros1 (reactive oxygen species 1) and eph (erythropoietin-producing hepatoma) are key targets of various agents currently in clinical development. |
2014-06-24 |
2023-08-12 |
human |
| Amanda I Phipps, Karen W Makar, Polly A Newcom. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. International journal of colorectal disease. vol 28. issue 12. 2014-06-18. PMID:23728594. |
approximately 10-30 % of colorectal cancers exhibit somatic mutations in the phosphoinositide-3-kinase, catalytic, alpha polypeptide gene (pik3ca). |
2014-06-18 |
2023-08-12 |
Not clear |
| G S Ducker, C E Atreya, J P Simko, Y K Hom, M R Matli, C H Benes, B Hann, E K Nakakura, E K Bergsland, D B Donner, J Settleman, K M Shokat, R S Warre. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. vol 33. issue 12. 2014-05-07. PMID:23542178. |
ras and phosphatidylinositol 3-kinase catalytic subunit alpha (pik3ca) mutations were the most significant genetic markers for resistance and sensitivity to pp242, respectively; colon origin was the most significant marker for resistance based on tissue type. |
2014-05-07 |
2023-08-12 |
human |
| Shuji Ogino, Xiaoyun Liao, Yu Imamura, Mai Yamauchi, Nadine J McCleary, Kimmie Ng, Donna Niedzwiecki, Leonard B Saltz, Robert J Mayer, Renaud Whittom, Alexander Hantel, Al B Benson, Rex B Mowat, Donna Spiegelman, Richard M Goldberg, Monica M Bertagnolli, Jeffrey A Meyerhardt, Charles S Fuch. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. Journal of the National Cancer Institute. vol 105. issue 23. 2014-02-03. PMID:24231454. |
somatic mutations in pik3ca (phosphatidylinositol-4,5-bisphosphonate 3-kinase [pi3k], catalytic subunit alpha gene) activate the pi3k-akt signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer. |
2014-02-03 |
2023-08-12 |
Not clear |
| Ariella B Hanker, Adam D Pfefferle, Justin M Balko, María Gabriela Kuba, Christian D Young, Violeta Sánchez, Cammie R Sutton, Hailing Cheng, Charles M Perou, Jean J Zhao, Rebecca S Cook, Carlos L Arteag. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. vol 110. issue 35. 2013-11-22. PMID:23940356. |
human epidermal growth factor receptor 2 (her2; erbb2) amplification and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca) mutations often co-occur in breast cancer. |
2013-11-22 |
2023-08-12 |
mouse |
| D S Meyer, S Koren, C Leroy, H Brinkhaus, U Müller, I Klebba, M Müller, R D Cardiff, M Bentires-Al. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis. vol 2. 2013-10-01. PMID:24080956. |
the gene encoding for the alpha catalytic subunit of pi3k (pik3ca) is mutated and/or amplified in ∼30% of breast cancers. |
2013-10-01 |
2023-08-12 |
mouse |
| Irina Palimaru, Anja Brügmann, Marie Kim Wium-Andersen, Ebba Nexo, Boe Sandahl Sorense. Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. SpringerPlus. vol 2. 2013-10-01. PMID:24083111. |
here, we explore differences in expression of important pi3k pathway regulators: the activator, phosphatidylinositol-3-kinase catalytic subunit alpha (pik3ca), and the tumour suppressor, phosphatase and tensin homolog (pten), in breast carcinoma tissue and normal breast tissue. |
2013-10-01 |
2023-08-12 |
Not clear |
| Sidra German, Hafiz Muhammad Aslam, Shafaq Saleem, Aisha Raees, Tooba Anum, Arsalan Ahmad Alvi, Abdul Hasee. Carcinogenesis of PIK3CA. Hereditary cancer in clinical practice. vol 11. issue 1. 2013-07-08. PMID:23768168. |
pik3ca is phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha. |
2013-07-08 |
2023-08-12 |
human |
| Muhammed Murtaza, Sarah-Jane Dawson, Dana W Y Tsui, Davina Gale, Tim Forshew, Anna M Piskorz, Christine Parkinson, Suet-Feung Chin, Zoya Kingsbury, Alvin S C Wong, Francesco Marass, Sean Humphray, James Hadfield, David Bentley, Tan Min Chin, James D Brenton, Carlos Caldas, Nitzan Rosenfel. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. vol 497. issue 7447. 2013-06-25. PMID:23563269. |
these included an activating mutation in pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) following treatment with paclitaxel; a truncating mutation in rb1 (retinoblastoma 1) following treatment with cisplatin; a truncating mutation in med1 (mediator complex subunit 1) following treatment with tamoxifen and trastuzumab, and following subsequent treatment with lapatinib, a splicing mutation in gas6 (growth arrest-specific 6) in the same patient; and a resistance-conferring mutation in egfr (epidermal growth factor receptor; t790m) following treatment with gefitinib. |
2013-06-25 |
2023-08-12 |
human |
| Michele Biscuola, Koen Van de Vijver, María Ángeles Castilla, Laura Romero-Pérez, María Ángeles López-García, Juan Díaz-Martín, Xavier Matias-Guiu, Esther Oliva, José Palacios Calv. Oncogene alterations in endometrial carcinosarcomas. Human pathology. vol 44. issue 5. 2013-06-20. PMID:23199529. |
eleven tumors (32.3%) had mutations affecting the pi3k (phosphoinositide-3-kinase)/akt (v-akt murine thymoma viral oncogene homolog 1) (6 mutations in pik3ca (pi3k catalytic alpha polypeptide) and 1 in akt) and/or ras/braf (serine/threonine-protein kinase b-raf) pathway (3 kras [kirsten ras oncogene homolog], 2 nras [neuroblastoma ras viral oncogene homolog], and 1 braf). |
2013-06-20 |
2023-08-12 |
human |
| Simonetta Piana, Moira Ragazzi, Giovanni Tallini, Dario de Biase, Alessia Ciarrocchi, Andrea Frasoldati, Juan Rosa. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. Human pathology. vol 44. issue 4. 2013-05-07. PMID:23079204. |
in addition to morphology, immunohistochemical (cyclin d1 and p53) and molecular analyses (braf [v-raf murine sarcoma viral oncogene homolog b1], kras [v-ki-ras2 kirsten rat sarcoma viral oncogene homolog], hras [v-ha-ras harvey rat sarcoma viral oncogene homolog], nras [neuroblastoma ras viral oncogene homolog], and pik3ca [phosphoinositide-3-kinase, catalytic, alpha polypeptide]) were performed. |
2013-05-07 |
2023-08-12 |
rat |